Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
Theravance Biopharma
TBPH
$878M
| $440K | ﹤0.01% |
+17,003
| New | +$330K |
|
|
RRTS
2952
DELISTED
RoadRunner Transportation Systems, Inc.
RRTS
| $438K | ﹤0.01% |
47,588
-10,000
| -17% | -$97.3K |
|
2953
Allegiant Air
ALGT
$2.36B
| $435K | ﹤0.01% |
2,500
-91,100
| -97% | -$15.1M |
|
2954
ClearOne Inc
CLRO
$15.2M
| $435K | ﹤0.01% |
17,452
+234
| +1% | +$6.04K |
|
2955
Savara
SVRA
$1.08B
| $435K | ﹤0.01% |
+97,182
| New | +$117K |
|
2956
iShares MSCI Netherlands ETF
EWN
$735M
| $433K | ﹤0.01% |
12,800
+3,700
| +41% | +$120K |
|
2957
i3 Verticals
IIIV
$323M
| $432K | ﹤0.01% |
+15,300
| New | +$361K |
|
|
IIN
2958
DELISTED
IntriCon Corporation
IIN
| $430K | ﹤0.01% |
23,900
+500
| +2% | +$9.58K |
|
2959
ProShares Short 20+ Year Treasury ETF
TBF
$106M
| $427K | ﹤0.01% |
21,800
-39,300
| -64% | -$756K |
|
|
RGLS
2960
DELISTED
Regulus Therapeutics
RGLS
| $425K | ﹤0.01% |
47,699
+7,030
| +17% | +$48.9K |
|
2961
Axogen
AXGN
$2.67B
| $424K | ﹤0.01% |
23,700
-94,400
| -80% | -$1.4M |
|
|
GSUM
2962
DELISTED
Gridsum Holding Inc.
GSUM
| $422K | ﹤0.01% |
345,826
-200
| -0.1% | -$379 |
|
2963
Cibus
CBUS
$145M
| $416K | ﹤0.01% |
1,188
+409
| +53% | +$103K |
|
|
MREO
2964
Mereo BioPharma
MREO
$49.1M
| $414K | ﹤0.01% |
126,323
-39,800
| -24% | -$102K |
|
|
RELV
2965
DELISTED
Reliv International Inc
RELV
| $414K | ﹤0.01% |
106,880
-400
| -0.4% | -$1.67K |
|
2966
CorMedix
CRMD
$639M
| $411K | ﹤0.01% |
+56,400
| New | +$345K |
|
|
AFH
2967
DELISTED
Atlas Financial Holdings, Inc. Ordinary Shares
AFH
| $411K | ﹤0.01% |
953,243
-8,063
| -0.8% | -$4.08K |
|
2968
iShares Russell 1000 ETF
IWB
$50.5B
| $410K | ﹤0.01% |
+2,300
| New | +$392K |
|
2969
Park-Ohio Holdings
PKOH
$716M
| $410K | ﹤0.01% |
12,183
-48,617
| -80% | -$1.53M |
|
2970
CEL-SCI Corp
CVM
$26M
| $408K | ﹤0.01% |
+1,486
| New | +$350K |
|
|
SDPI
2971
DELISTED
Superior Drilling Products Inc.
SDPI
| $408K | ﹤0.01% |
497,724
+9,678
| +2% | +$8.57K |
|
|
DLA
2972
DELISTED
Delta Apparel Inc.
DLA
| $404K | ﹤0.01% |
13,000
+600
| +5% | +$16.1K |
|
|
YIN
2973
DELISTED
Yintech Investment Holdings Limited American Depositary Shares
YIN
| $403K | ﹤0.01% |
76,035
+4,100
| +6% | +$19.9K |
|
|
IHC
2974
DELISTED
Independence Holding Company
IHC
| $403K | ﹤0.01% |
9,570
+568
| +6% | +$22.8K |
|
2975
Amplify Cybersecurity ETF
HACK
$3.08B
| $399K | ﹤0.01% |
+9,600
| New | +$384K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.